secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2026-08-19T20:04:17+00:00
Accession:  0001140361-26-033738
Event type: m_and_a
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics supplements proxy disclosures amid shareholder lawsuits over Vertex merger
--------------------------------------------------------------------------------

- Three shareholder lawsuits filed Aug 6 & 17, 2026 in NY and CA allege misleading proxy disclosures; seek to block merger.
- Board unanimously reaffirms 'FOR' recommendation on merger and related proposals; special shareholder meeting set for Aug 28, 2026.
- Supplemental disclosures add J.P. Morgan and Leerink valuation analyses; updated projections show revenue rising to $1,057M by 2030E and $4,583M by 2035E.
- Advisor fees disclosed: J.P. Morgan ~$69.4M and Leerink ~$60.8M, largely contingent on $85.00/share deal closing.
- Company denies allegations, says proxy complies with law; voluntary supplements made to avoid nuisance and potential delays.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000114036126033738/0001140361-26-033738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000114036126033738/ef20080494_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-033738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer